The Pre-Commercial Exit: What Most Medtech Founders & Boards Get Wrong

Most founders who've built a serious pre-commercial medical device company have a working sense of what an exit might look like. Usually not a precise number (the comps are too thin and too hidden for that) but a range, built from conversations with investors, from what the last round implied, from what they've heard secondhand about deals in adjacent categories, and from past exits they may have achieved.

That range is usually wrong. Not wrong in a way that reflects naivety or lack of intelligence, but wrong because they are only signals with no grounding in the deal structure and universal premises upon which valuations are founded. An error in perception of your current or anticipated value will skew many, if not all, of your corporate decisions, but no more so than when you’re at the exit decision.

Here's where the gap between your inkling and a formal valuation typically lives.

Your acquirer's model is not your investor's model

When your investors priced your last round, they were buying a minority stake with preferred rights, downside protection, and a portfolio construction logic that has nothing to do with your company specifically. The price reflected market conditions, deal dynamics, and their thesis about the category. It was, in many ways, a price for the option on your success.

A strategic acquirer is buying the asset outright, and they're running a very different calculation. Their corporate development team will project your device's revenue, margin, and market share assuming successful commercialization, then multiply every year of those projections by the cumulative probability of actually getting there -  through IDE, through 510(k) or PMA, through reimbursement, through commercial launch. Those probabilities compound. A device with a 70% chance of clearance and a 60% chance of achieving meaningful reimbursement coverage is being priced at roughly 42 cents on the dollar of its commercial potential. That may be a hard pill to swallow, but it’s pragmatic and it’s the model.

The gap between your last round price and an acquirer's initial offer isn't a reflection of how they value your technology. It's a reflection of a totally different risk matrix.

Comparables will not help you the way you hope

Experienced founders know to look for transaction comparables before entering a process. The problem is that the deals most relevant to your situation (smaller pre-commercial or early-commercial tuck-ins in your specific category) are largely invisible.

Below a certain threshold, public company acquirers aren't required to disclose deal terms in earnings filings because the transaction doesn't rise to materiality. Private-to-private deals carry no disclosure requirement at all. NDAs cover the rest. And the medical device trade media, which covers the headline transactions that moved a large-cap's stock price, usually has little appetite for the details of a $40 million tuck-in that nobody's talking about publicly.

This isn't a research problem you can solve by looking harder. The data simply isn't there. What it means practically is that your negotiating position in a process relies far more on competitive tension between real bidders than on an analytical argument about what (arguably) comparable assets have fetched. Boards that go into a process believing they can anchor the price with comp data are often surprised to find themselves without a credible floor.

Where first time exit founders leave money on the table 

Every founder who has been through a prior exit will tell you to take the headline value (the big, overall transaction number) with a massive grain of salt. Understanding the headline valuation mechanics is useful but where value still gets left on the table is typically in the interaction between deal structure and the acquirer's post-close incentives.

Here’s what I mean: An offer that looks like $80 million is doing different things depending on how it's built. $40M up-front cash at close, $20M tied to regulatory clearance, $20M tied to first-year revenue against a commercial plan the acquirer controls isn’t really an $80 million exit. It's a $40 million exit with $40 million in contingent consideration that the acquirer has limited contractual obligation to pursue aggressively and that you have no control over.

Earn-out structures in particular are where sophisticated acquirers recover margin post-close. Milestones get set against timelines that require resources the acquirer controls. "Commercially reasonable efforts" language, without specificity, is effectively unenforceable. A well-represented seller at a smaller deal size, where the acquirer's legal team has seen this structure hundreds of times and the seller's team may not have, tends to come out worse than they expected on the back end.

This same dynamic applies to escrow. Five to fifteen percent of deal value held for twelve to twenty-four months is standard, and at the high end of that range for any company with open FDA observations or regulatory uncertainty. It's a structural feature of medtech deals, and founders who haven't modeled their actual at-close proceeds,  including the escrow hold and the preferred waterfall on their cap table, are often surprised and disappointed by the number they receive. 

The timing decision most boards make by instinct

There's a decision that sits underneath all of this, and it's the one that most boards reach by instinct, exhaustion, or a fast approaching runway end rather than by deliberate analysis.

Sell before clearance and you're handing the acquirer the regulatory execution risk which they’ll price in accordingly. But you're also leaving that step-up on the table, assuming you have the runway and the clinical risk profile to get there.

Wait for clearance and you've converted the biggest single discount in the acquirer's rNPV model into something that no longer needs to be discounted. But the competitive landscape may have shifted. The acquirer who was most interested twelve months ago has made a different acquisition. The M&A environment in your category has tightened.

Most boards make this decision based on fundraising pressure, investor sentiment, or a conversation with a single interested party who happened to reach out at the right moment. Very few make it based on a structured analysis of what the clearance premium is actually worth in their specific situation, what the realistic probability of achieving it is, and what the acquirer landscape looks like on both sides of that milestone.

That analysis, done rigorously, before the pressure is on is usually where the most value is created or destroyed in a pre-commercial exit. Not in the negotiation itself.

What this means for a board at the decision point

The question isn't whether your company is fundable or whether the technology works. If you've built to this stage, you've answered both of those successfully. The question is what a specific set of acquirers would pay for your medical technology asset today versus in eighteen months, whether you can create competitive tension among them, and whether the structure of the deal you're likely to receive actually delivers what the headline suggests.

Those are answerable questions but they require a different kind of analysis than the one most boards are doing when they're deciding whether to raise another round.

Amanda Cooper advises the boards of pre-commercial and early-commercial medical device companies navigating the raise-or-exit decision and provides detailed roadmaps for those who choose the latter.